Table 1.
General characteristics of participants.
| Characteristics | Before PS Overlap Weighting Adjustment | After PS Overlap Weighting Adjustment | ||||
|---|---|---|---|---|---|---|
| Brain Tumor | Control | Standardized Difference |
Brain Tumor | Control | Standardized Difference |
|
| Age (n, %) | 0.00 | 0.00 | ||||
| 0–4 | 18 (0.95) | 72 (0.95) | 10 (0.84) | 10 (0.84) | ||
| 5–9 | 35 (1.85) | 140 (1.85) | 21 (1.77) | 21 (1.77) | ||
| 10–14 | 39 (2.06) | 156 (2.06) | 22 (1.87) | 22 (1.87) | ||
| 15–19 | 58 (3.06) | 232 (3.06) | 38 (3.26) | 38 (3.26) | ||
| 20–24 | 53 (2.80) | 212 (2.80) | 34 (2.91) | 34 (2.91) | ||
| 25–29 | 41 (2.17) | 164 (2.17) | 27 (2.33) | 27 (2.33) | ||
| 30–34 | 66 (3.49) | 264 (3.49) | 42 (3.62) | 42 (3.62) | ||
| 35–39 | 92 (4.86) | 368 (4.86) | 56 (4.87) | 56 (4.87) | ||
| 40–44 | 147 (7.77) | 588 (7.77) | 94 (8.11) | 94 (8.11) | ||
| 45–49 | 159 (8.40) | 636 (8.40) | 99 (8.59) | 99 (8.59) | ||
| 50–54 | 189 (9.98) | 756 (9.98) | 118 (10.24) | 118 (10.24) | ||
| 55–59 | 178 (9.40) | 712 (9.40) | 110 (9.54) | 110 (9.54) | ||
| 60–64 | 186 (9.83) | 744 (9.83) | 116 (10.02) | 116 (10.02) | ||
| 65–69 | 213 (11.25) | 852 (11.25) | 125 (10.85) | 125 (10.85) | ||
| 70–74 | 177 (9.35) | 708 (9.35) | 104 (9.03) | 104 (9.03) | ||
| 75–79 | 134 (7.08) | 536 (7.08) | 79 (6.84) | 79 (6.84) | ||
| 80–84 | 78 (4.12) | 312 (4.12) | 44 (3.82) | 44 (3.82) | ||
| 85+ | 30 (1.58) | 120 (1.58) | 17 (1.50) | 17 (1.50) | ||
| Sex (n, %) | 0.00 | 0.00 | ||||
| Male | 855 (45.17) | 3420 (45.17) | 509 (44.01) | 509 (44.01) | ||
| Female | 1038 (54.83) | 4152 (54.83) | 647 (55.99) | 647 (55.99) | ||
| Income (n, %) | 0.00 | 0.00 | ||||
| 1 (lowest) | 344 (18.17) | 1376 (18.17) | 204 (17.63) | 204 (17.63) | ||
| 2 | 218 (11.52) | 872 (11.52) | 132 (11.42) | 132 (11.42) | ||
| 3 | 290 (15.32) | 1160 (15.32) | 177 (15.30) | 177 (15.30) | ||
| 4 | 449 (23.72) | 1796 (23.72) | 275 (23.80) | 275 (23.80) | ||
| 5 (highest) | 592 (31.27) | 2368 (31.27) | 368 (31.85) | 368 (31.85) | ||
| Region of residence (n, %) | 0.00 | 0.00 | ||||
| Urban | 849 (44.85) | 3396 (44.85) | 525 (45.41) | 525 (45.41) | ||
| Rural | 1044 (55.15) | 4176 (55.15) | 631 (54.59) | 631 (54.59) | ||
| CCI score (Mean, SD) | 2.57 (2.44) | 0.54 (1.21) | 1.05 | 1.47 (1.31) | 1.47 (0.84) | 0.00 |
| Diabetes history (n, %) | 526 (27.79) | 1898 (25.07) | 0.06 | 311 (26.90) | 311 (26.90) | 0.00 |
| Dyslipidemia and Statin prescription dates (n, %) | 0.17 | 0.18 | ||||
| Normal | 1160 (61.28) | 4457 (58.86) | 677 (58.51) | 678 (58.64) | ||
| Dyslipidemia without Statin | 349 (18.44) | 1860 (24.56) | 229 (19.84) | 290 (25.08) | ||
| Dyslipidemia with <365 days | 184 (9.72) | 509 (6.72) | 119 (10.31) | 77 (6.65) | ||
| Dyslipidemia with ≥365 days | 200 (10.57) | 746 (9.85) | 131 (11.35) | 111 (9.63) | ||
| Dyslipidemia and Lipophilic Statin prescription dates (n, %) | 0.16 | 0.15 | ||||
| Normal | 1160 (61.28) | 4457 (58.86) | 677 (58.51) | 678 (58.64) | ||
| Dyslipidemia without Lipophilic Statin |
418 (22.08) | 2131 (28.14) | 276 (23.83) | 328 (28.36) | ||
| Dyslipidemia with <365 days | 163 (8.61) | 461 (6.09) | 105 (9.05) | 70 (6.05) | ||
| Dyslipidemia with ≥365 days | 152 (8.03) | 523 (6.91) | 100 (8.62) | 81 (6.96) | ||
| Dyslipidemia and Hydrophilic Statin prescription dates (n, %) | 0.11 | 0.10 | ||||
| Normal | 1160 (61.28) | 4457 (58.86) | 677 (58.51) | 678 (58.64) | ||
| Dyslipidemia without Hydrophilic Statin |
607 (32.07) | 2698 (35.63) | 397 (34.36) | 417 (36.05) | ||
| Dyslipidemia with <365 days | 85 (4.49) | 222 (2.93) | 55 (4.75) | 34 (2.92) | ||
| Dyslipidemia with ≥365 days | 41 (2.17) | 195 (2.58) | 28 (2.38) | 28 (2.39) | ||
| Dyslipidemia (n, %) | 733 (38.72) | 3115 (41.14) | 0.05 | 480 (41.49) | 478 (41.36) | 0.00 |
| Statin prescription dates (n, %) | 0.19 | 0.18 | ||||
| Non-user | 1416 (74.80) | 6151 (81.23) | 860 (74.35) | 936 (80.94) | ||
| <365 days | 254 (13.42) | 592 (7.82) | 153 (13.19) | 94 (8.12) | ||
| ≥365 days | 223 (11.78) | 829 (10.95) | 144 (12.46) | 127 (10.94) | ||
| Lipophilic Statin prescription dates (n, %) | 0.18 | 0.16 | ||||
| Non-user | 1498 (79.13) | 6449 (85.17) | 914 (79.02) | 979 (84.63) | ||
| <365 days | 224 (11.83) | 531 (7.01) | 132 (11.41) | 85 (7.39) | ||
| ≥365 days | 171 (9.03) | 592 (7.82) | 111 (9.57) | 92 (7.99) | ||
| Hydrophilic Statin prescription dates (n, %) | 0.10 | 0.10 | ||||
| Non-user | 1747 (92.29) | 7114 (93.95) | 1063 (91.93) | 1086 (93.92) | ||
| <365 days | 101 (5.34) | 250 (3.30) | 64 (5.52) | 40 (3.42) | ||
| ≥365 days | 45 (2.38) | 208 (2.75) | 29 (2.54) | 31 (2.66) | ||
Abbreviations: CCI, Charlson Comorbidity Index; PS, Propensity score; N/A, Not applicable.